Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)
Status:
Not yet recruiting
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of cryoablation combined
with Tislelizumab plus Lenvatinib as first-line treatment in patients with advanced HCC.